|
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $0.68 | - | - |
| Q1'26 | $0.72 | $0.75 | +3.9% |
| Q4'25 | $0.58 | $0.66 | +14.3% |
| Q3'25 | $0.63 | $0.87 | +37.4% |
| Q2'25 | $0.57 | $0.78 | +35.9% |
| Q1'25 | $0.67 | $0.92 | +36.5% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $14.6B | - | - |
| Q1'26 | $13.8B | $14.5B | +4.7% |
| Q4'25 | $17.1B | $17.6B | +2.6% |
| Q3'25 | - | $16.7B | - |
| Q2'25 | - | $14.7B | - |
| Q1'25 | - | $13.7B | - |
Market Data
PFE is currently trading at $25.78, giving Pfizer Inc. a market cap of 146.62B and a P/E ratio of 19.6. Today's range spans $25.24–$25.87, with shares opening at $25.73 and moving up $0.03 (0.1%) from the prior close. DailyIQ's technical score sits at 14/100 (SELL) with a news sentiment reading of 76/100.
Over the past year PFE has traded between $21.97 and $28.75 - the current price is +17.3% off the 52-week low and -10.3% from the high. 36 analysts cover the stock with a Hold consensus and a mean 12-month target of $29.15 (range $24.00–$36.00), implying upside of +13.1%.
PFE: large-cap, Healthcare, 146.62B market cap. (P/E: 19.6) Technical score 14/100 (SELL). Sentiment: bullish (76/100). Price: $25.78 (in the middle of its 52-week range). Range: $21.97–$28.75. The SELL designation at this capitalization tier doesn't mean the stock is uninvestable - it means the risk/reward of buying dips hasn't been restored yet, and patience or an outright hedge is often the better posture until technical conditions improve.
When a large-cap Healthcare name with 146.62B in capitalization prints a SELL signal (14/100) alongside bullish news sentiment (76/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $25.78 (in the middle of its 52-week range in the $21.97–$28.75 range), the structural support levels are where that sponsorship question gets answered.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).